What Curza does

Curza is a privately held, clinical-stage small-molecule therapeutics company headquartered in Salt Lake City, Utah, developing structurally distinct classes of proprietary antibiotics to combat antimicrobial resistance (AMR). The company's scientific platform is built around targeting a highly conserved, previously undrugged binding site on the bacterial ribosome, yielding novel chemical classes with activity against ESKAPE pathogens — Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli — with particular focus on drug-resistant Gram-negative bacteria. The lead program, CZ-02, is a broad-spectrum antibiotic inspired by a natural product and is being prepared for clinical-phase development. A second core program, the antibiofilm antibiotic series, is positioned as first-in-class for killing and eradicating bacteria in the biofilm phenotype, with potential applications in tuberculosis, diabetic ulcers, Lyme disease, osteomyelitis, medical device-related infections, chronic skin wounds, and cystic fibrosis-related infections.

The company is pre-revenue and does not yet have approved or commercialized products; it generates no product sales, licensing royalties, or contract revenue. Its operating model is a non-dilutive-capital-heavy R&D structure, funded by a mix of federal grants from NIAID, DTRA, NCI, FDA, NSF, the Department of Veterans Affairs, and the Department of Defense, supplemented by milestone-based funding from CARB-X and equity investments from Clarke Capital Partners and Novo Holdings' REPAIR Impact Fund. Leadership is anchored by CEO Chad Testa, PhD (formerly SVP of R&D at Echelon Biosciences), with a senior team and board carrying credentials from Merck, GlaxoSmithKline, Pfizer, Amgen, Eli Lilly, AstraZeneca, Pharmacia, and academic institutions including the University of Utah, University of Florida, Harvard, MIT, UCLA, and Colorado State. Go-to-market is future-oriented: distribution is expected to flow through pharmaceutical partnerships, licensing, or co-development arrangements with major pharmaceutical companies for global commercialization of approved antibiotics. Target end-users are hospitals, clinics, and healthcare systems treating patients with drug-resistant and biofilm-related infections, with a secondary use case in bacterial biothreat defense for government and defense agencies.

Name

Curza

Legal name

Curza

Website

https://curza.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Curza is a pre-revenue, privately held small-molecule therapeutics company developing proprietary antibiotic classes against drug-resistant ESKAPE pathogens and biofilm-related infections, with a lead program (CZ-02) targeting an unexploited bacterial ribosomal site. It serves future hospital and biodefense markets via anticipated pharmaceutical partnerships.

Ownership category

akta.pro rank

Product category

Antibiotic Drug Development

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

Keywords

• Small-molecule therapeutics
• Novel antibiotics development
• Antimicrobial resistance drugs
• Antibiofilm therapeutics
• ESKAPE pathogen treatments

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels3 records

Core offering

Curza is a clinical-stage small-molecule therapeutics company developing proprietary antibiotic drug classes to combat antimicrobial resistance (AMR). Its pipeline includes the lead program CZ-02 (a new class of broad-spectrum antibiotics targeting drug-resistant Gram-negative bacteria via an unexploited binding site of the bacterial ribosome), Ribosomal Antibiotics against ESKAPE 'superbugs', and first-in-class Antibiofilm Antibiotics for biofilm-related infections such as tuberculosis, diabetic ulcers, and medical device infections.

Product overview

Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. The company's pipeline includes three core programs: the lead program CZ-02 (a new class of broad-spectrum antibiotics targeting drug-resistant Gram-negative bacteria via the bacterial ribosome), Ribosomal Antibiotics (two novel antibiotic classes targeting ESKAPE pathogens), and Antibiofilm Antibiotics (first-in-class compounds for treating biofilm-related infections). The company is preparing these distinct structural classes for clinical phase development.

Differentiator

Problem solved

Functional benefit

Products and services

• CZ-02 Lead program: a new class of broad-spectrum antibiotics focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, it targets an unexploited binding site of the bacterial ribosome.
• Ribosomal Antibiotics Program comprising two novel classes of antibiotics designed to show selectivity and potent activity against ESKAPE pathogens including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli.
• Antibiofilm Antibiotics First-in-class series of antibiofilm antibiotics specifically designed to kill and eradicate bacteria in the biofilm phenotype. Applications include tuberculosis, diabetic ulcers, Lyme disease, medical device-related infections, osteomyelitis, chronic skin wounds, and cystic fibrosis-related infections.

Quantifiable outcome

• Novel class of antibiotics targeting ESKAPE pathogens with selectivity and potent activity
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• University of FloridacoreStrategic or Co-development Partner · 1 April 2021Curza and the University of Florida expanded their collaboration to include bacterial biothreats, supported by a DTRA award. The collaboration focuses on antibiotic development targeting drug-resistant bacteria and bacterial biothreats.
• Jon M. Huntsman Presidential Chair Program (University of Utah)coreStrategic or Co-development PartnerRyan E. Looper, PhD, Senior Vice President of Discovery, holds the Jon M. Huntsman Presidential Chair in Chemistry at the University of Utah. This academic partnership provides access to research expertise in natural product synthesis, chemical biology, and medicinal chemistry.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia; overlaps with Curza's antibiofilm approach at the microbiome/anti-infective interface.
• Seres Therapeutics: Clinical-stage microbiome therapeutics company; comparable in that both companies target microbiome-mediated and biofilm-phenotype infection biology, though with different modalities.
• Cidara Therapeutics: Biotech focused on anti-infectives including antivirals and antibacterial conjugates; overlapping anti-infective development focus though with different mechanisms.

Direct peers

• Entasis Therapeutics: Clinical-stage antibiotic company targeting drug-resistant Gram-negative infections and ESKAPE pathogens using differentiated small-molecule chemistry; was acquired by Innoviva in 2022. Direct mechanistic and indication overlap with Curza's CZ-02 program.
• Tetraphase Pharmaceuticals: Developed eravacycline, a novel antibiotic for drug-resistant infections including ESKAPE pathogens; acquired by La Jolla Pharmaceutical Company in 2020. Comparable business model as a focused, small-molecule antibiotic developer.
• Iterum Therapeutics: Clinical-stage anti-infectives company developing oral and IV antibiotics for drug-resistant Gram-negative bacteria; competes in the same AMR therapeutic space as Curza.
• Nabriva Therapeutics: Develops novel antibiotics for serious infections including drug-resistant pathogens, with both branded and hospital-focused programs. Comparable pre-commercial-stage anti-infective developer.
• Melinta Therapeutics: Developer and commercializer of FDA-approved antibiotics for drug-resistant infections; illustrates the commercial-stage endpoint for companies like Curza and is a benchmark for AMR-targeted antibiotic strategy.

Others

• Achaogen: Predecessor-era antibiotic developer of plazomicin for drug-resistant Gram-negative infections; filed for bankruptcy in 2019, serving as a cautionary strategic comparable for novel-mechanism antibiotic companies like Curza.
• CARB-X: Global non-dilutive accelerator funding antibacterial R&D; not a competitor but a key funder and ecosystem participant that has backed Curza and 100+ peer antibacterial projects since 2016.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/curzausa
• Facebookfacebook.com/curzausa
• LinkedInlinkedin.com/company/curza-global

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curza